Total trials
56
Active
19
Phase 3
1
Total enrollment
24,438
Pipeline matrix
Showing 40 of 40 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Everolimus | — | — | — | — | — | 1 | |
| Elacestrant | — | — | — | — | — | 1 | |
| Auxiliary Medicinal Product - Dexamethasone | — | — | — | — | — | 1 | |
| Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues | — | — | — | — | — | 1 | |
| Trastuzumab deruxtecan | — | — | — | — | — | 3 | |
| Carboplatin | — | — | — | — | — | 3 | |
| Eribulin | — | — | — | — | — | 6 | |
| Pembrolizumab | — | — | — | — | — | 4 | |
| Fulvestrant | — | — | — | — | — | 4 | |
| Letrozole | — | — | — | — | — | 4 | |
| Paclitaxel | — | — | — | — | — | 3 | |
| Sacituzumab Govitecan | — | — | — | — | — | 3 | |
| Capecitabine | — | — | — | — | — | 3 | |
| Tamoxifen | — | — | — | — | — | 3 | |
| Niraparib | — | — | — | — | — | 2 | |
| Tucatinib | — | — | — | — | — | 2 | |
| Giredestrant | — | — | — | — | — | 2 | |
| Abemaciclib | — | — | — | — | — | 2 | |
| bexmarilimab | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Debio 0123 and Sacituzumab govitecan | — | — | — | — | — | 1 | |
| Trastuzumab and Pertuzumab (FDC SC) and T-DM1 | — | — | — | — | — | 1 | |
| Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML | — | — | — | — | — | 1 | |
| Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL | — | — | — | — | — | 1 | |
| CDK4/6i plus ET | — | — | — | — | — | 1 | |
| MEN1611 | — | — | — | — | — | 1 | |
| Repotrectinib | — | — | — | — | — | 1 | |
| Trastuzumab-Deruxtecan | — | — | — | — | — | 1 | |
| Perjeta | — | — | — | — | — | 1 | |
| Herceptin | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Zongertinib | — | — | — | — | — | 1 | |
| Zanidatamab | — | — | — | — | — | 1 | |
| Eribulin Mesilate | — | — | — | — | — | 1 | |
| Atropine | — | — | — | — | — | 1 | |
| G-CSF | — | — | — | — | — | 1 | |
| Inavolisib | — | — | — | — | — | 1 | |
| Radiotracer targeting somatostatin receptor 2 | — | — | — | — | — | 1 | |
| Camizestrant | — | — | — | — | — | 1 | |
| Ribociclib | — | — | — | — | — | 1 |
Next readouts
- 2023-11-01
- 2026-04
- 2026-08
- 2026-11
- 2026-11-30
- 2027-01
- 2027-02
- 2027-03
- 2027-03
- 2027-04
Top conditions
- Breast Cancer18
- Advanced Breast Cancer13
- Metastatic Breast Cancer9
- Triple Negative Breast Cancer5
- HER2-positive Breast Cancer4
- Breast Cancer Metastatic3
- Advanced HR+/HER2- Breast Cancer2
- Early Breast Cancer2
Frequently asked questions about MedSIR
- How many clinical trials does MedSIR have on ClinicalTrials.gov?
- MedSIR is listed as the lead sponsor on 56 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of MedSIR's trials are in Phase 3?
- 1 of MedSIR's trials are in Phase 3, spread across 40 active drug programs.
- What therapeutic areas does MedSIR focus on?
- MedSIR's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer.
- When are MedSIR's next clinical trial readouts?
- MedSIR has 10 upcoming primary-completion readouts tracked here; the soonest is “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.”, expected around 2023-11-01.